Persistent B-cell depletion after rituximab for thrombocytopenic purpura.
Bisogno
Gianni
G
Division of Hematology/Oncology, Department of Pediatrics, University Hospital of Padova, Via Giustiniani 3, 35128 Padova, Italy. gianni.bisogno@unipd.it
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000187:drug effects*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab